The first step is to eliminate or treat causes of intracranial hypertension. If the diagnosis is IIH, a weight-reduction program can be instituted and, if indicated, pharmacologic therapy can be started with the aim of reversing and preventing loss of vision. Treatment can be given for headache if it persists despite use of intracranial pressure-lowering agents and procedures.[1]Wall M. Idiopathic intracranial hypertension. Neurol Clin. 2010 Aug;28(3):593-617.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908600
http://www.ncbi.nlm.nih.gov/pubmed/20637991?tool=bestpractice.com
[46]Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1088-100.
https://jnnp.bmj.com/content/89/10/1088.long
http://www.ncbi.nlm.nih.gov/pubmed/29903905?tool=bestpractice.com
Elimination or treatment of other causal factors
Other potential causal factors need to be identified (see Diagnostic approach for more information). If an underlying cause for the intracranial hypertension is found, this should be treated appropriately. Tetracyclines, retinoids, and excessive vitamin A should be discontinued. In the setting of corticosteroid withdrawal, restart corticosteroid therapy and taper slowly.
Weight reduction
Studies show that weight-reduction diets can reduce intracranial pressure and papilledema in patients with IIH.[11]Johnson LN, Krohel GB, Madsen RW, et al. The role of weight loss and acetazolamide in the treatment of idiopathic intracranial hypertension (pseudotumor cerebri). Ophthalmology. 1998 Dec;105(12):2313-7.
http://www.ncbi.nlm.nih.gov/pubmed/9855165?tool=bestpractice.com
[54]NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014 Apr 23-30;311(16):1641-51.
http://jama.jamanetwork.com/article.aspx?articleid=1861803
http://www.ncbi.nlm.nih.gov/pubmed/24756514?tool=bestpractice.com
[56]Newborg B. Pseudotumor cerebri treated by rice reduction diet. Arch Intern Med. 1974 May;133(5):802-7.
http://www.ncbi.nlm.nih.gov/pubmed/4821775?tool=bestpractice.com
Patients should aim to lose 5% to 10% of their total body weight, and maintain the weight loss. This is a more realistic goal than other diet plans, so is more likely to be achieved than if the patient aims for greater weight loss. In one prospective cohort study, the improvement in symptoms persisted for 3 months after the patients stopped the diet.[57]Sinclair AJ, Burdon MA, Nightingale PG, et al. Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study. BMJ. 2010 Jul 7;341:c2701.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898925
http://www.ncbi.nlm.nih.gov/pubmed/20610512?tool=bestpractice.com
Patients with IIH and class III obesity (body mass index >40) have poor results with dietary therapy and should be considered for bariatric surgery.[58]Amaral JF, Tsiaris W, Morgan T, et al. Reversal of benign intracranial hypertension by surgically induced weight loss. Arch Surg. 1987 Aug;122(8):946-9.
http://www.ncbi.nlm.nih.gov/pubmed/3632342?tool=bestpractice.com
[59]Sugerman HJ, Felton WL 3rd, Sismanis A, et al. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg. 1999 May;229(5):634-40.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1420807
http://www.ncbi.nlm.nih.gov/pubmed/10235521?tool=bestpractice.com
A review of published literature found 56 of 61 patients with IIH had resolution of symptoms following surgery.[60]Fridley J, Foroozan R, Sherman V, et al. Bariatric surgery for the treatment of idiopathic intracranial hypertension. J Neurosurg. 2011 Jan;114(1):34-9.
http://www.ncbi.nlm.nih.gov/pubmed/20095788?tool=bestpractice.com
Surgery also addresses additional obesity-related comorbidities. Due to the risk of complications, surgery should be limited to this patient group only.[59]Sugerman HJ, Felton WL 3rd, Sismanis A, et al. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg. 1999 May;229(5):634-40.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1420807
http://www.ncbi.nlm.nih.gov/pubmed/10235521?tool=bestpractice.com
Low-sodium diet
Patients are advised to follow a low-sodium diet and to only drink when thirsty (instead of forcing water intake), because excessive water intake may contribute to increased intracranial pressure. A low-sodium diet and mild fluid restriction may be beneficial for patients with IIH who have orthostatic edema.[61]Friedman DI, Streeten DH. Idiopathic intracranial hypertension and orthostatic edema may share a common pathogenesis. Neurology. 1998 Apr;50(4):1099-104.
http://www.ncbi.nlm.nih.gov/pubmed/9566401?tool=bestpractice.com
Medical therapy to decrease intracranial pressure
At initial presentation, many patients are symptomatic, have mild loss of vision, and have a moderate degree of papilledema. In addition to a low-sodium weight-reduction program and the elimination of causal factors, these patients may be started on medical therapy.
Acetazolamide
Acetazolamide works by inhibiting carbonic anhydrase, which causes a reduction in transport of sodium ions across the choroid plexus epithelium, but the mechanism of action is likely multifactorial. Acetazolamide decreases cerebrospinal fluid (CSF) production in humans by 6% to 50%.[62]Rubin RC, Henderson ES, Ommaya AK, et al. The production of cerebrospinal fluid in man and its modification by acetazolamide. J Neurosurg. 1966 Oct;25(4):430-6.
http://www.ncbi.nlm.nih.gov/pubmed/5925714?tool=bestpractice.com
Evidence suggests that the use of acetazolamide with a low-sodium weight-reduction diet improves visual field function in patients with IIH and mild visual loss.[54]NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014 Apr 23-30;311(16):1641-51.
http://jama.jamanetwork.com/article.aspx?articleid=1861803
http://www.ncbi.nlm.nih.gov/pubmed/24756514?tool=bestpractice.com
The combination of acetazolamide and diet has also been shown to significantly improve papilledema grade, quality-of-life measures, and CSF pressure at 6 months.[54]NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014 Apr 23-30;311(16):1641-51.
http://jama.jamanetwork.com/article.aspx?articleid=1861803
http://www.ncbi.nlm.nih.gov/pubmed/24756514?tool=bestpractice.com
[63]Smith SV, Friedman DI. The idiopathic intracranial hypertension treatment trial: a review of the outcomes. Headache. 2017 Sep;57(8):1303-10.
http://www.ncbi.nlm.nih.gov/pubmed/28758206?tool=bestpractice.com
However, one Cochrane review concluded that there was insufficient evidence for the use of acetazolamide and it was unclear whether possible benefits outweighed the increased risk of side effects compared with placebo.[64]Piper RJ, Kalyvas AV, Young AM, et al. Interventions for idiopathic intracranial hypertension. Cochrane Database Syst Rev. 2015 Aug 7;(8):CD003434.
https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD003434.pub3/full
http://www.ncbi.nlm.nih.gov/pubmed/26250102?tool=bestpractice.com
The patient should take acetazolamide until symptoms and signs regress, or if side effects interfere with daily activities.[65]Lubow M, Kuhr L. Pseudotumor cerebri: comments on practical management. In: Glaser JS, Smith JL, eds. Neuro-ophthalmology, Vol. IX. St Louis, MO: CV Mosby; 1976:199-206.[66]Tomsak RL, Niffenegger AS, Remler BF. Treatment of pseudotumor cerebri with Diamox (acetazolamide). J Clin Neuroophthalmol. 1988;8:93-8. The maximum tolerated dosage should be taken, which sometimes requires down-titrating until side effects improve and then slowly increasing the titration. Patients with more severe visual loss need a higher initial dosage and a more rapid titration.
Adverse effects of acetazolamide include: changes to the taste of food and drink (which may result in weight loss); tingling in the fingers, toes, and perioral region; malaise; renal stones; metabolic acidosis; hypokalemia (particularly when combined with other diuretics); aplastic anemia (rarely).[54]NORDIC Idiopathic Intracranial Hypertension Study Group Writing Committee; Wall M, McDermott MP, Kieburtz KD, et al. Effect of acetazolamide on visual function in patients with idiopathic intracranial hypertension and mild visual loss: the idiopathic intracranial hypertension treatment trial. JAMA. 2014 Apr 23-30;311(16):1641-51.
http://jama.jamanetwork.com/article.aspx?articleid=1861803
http://www.ncbi.nlm.nih.gov/pubmed/24756514?tool=bestpractice.com
[67]Lichter PR. Reducing side effects of carbonic anhydrase inhibitors. Ophthalmology. 1981 Mar;88(3):266-9.
http://www.ncbi.nlm.nih.gov/pubmed/7231916?tool=bestpractice.com
[68]Garner LL, Carl EF, Ferwerda JR. Advantages of sustained-release therapy with acetazolamide in glaucoma. Am J Ophthalmol. 1963;55:323-7.[69]Zimran A, Beutler E. Can the risk of acetazolamide-induced aplastic anemia be decreased by periodic monitoring of blood cell counts? Am J Ophthalmol. 1987 Dec 15;104(6):654-8.
http://www.ncbi.nlm.nih.gov/pubmed/3688107?tool=bestpractice.com
[70]ten Hove MW, Friedman DI, Patel AD, Irrcher I, et al; NORDIC Idiopathic Intracranial Hypertension Study Group. Safety and tolerability of acetazolamide in the Idiopathic Intracranial Hypertension Treatment Trial. J Neuroophthalmol. 2016 Mar;36(1):13-9.
http://www.ncbi.nlm.nih.gov/pubmed/26587993?tool=bestpractice.com
Furosemide
Treatment can be switched from acetazolamide to furosemide.[71]Corbett JJ. The 1982 Silversides lecture: problems in the diagnosis and treatment of pseudotumor cerebri. Can J Neurol Sci. 1983 Nov;10(4):221-9.
http://www.ncbi.nlm.nih.gov/pubmed/6652584?tool=bestpractice.com
[72]Pollay M, Fullenwider C, Roberts PA, et al. Effect of mannitol and furosemide on blood-brain osmotic gradient and intracranial pressure. J Neurosurg. 1983 Dec;59(6):945-50.
http://www.ncbi.nlm.nih.gov/pubmed/6415245?tool=bestpractice.com
[73]Roberts PA, Pollay M, Engles C, et al. Effect on intracranial pressure of furosemide combined with varying doses and administration rates of mannitol. J Neurosurg. 1987 Mar;66(3):440-6.
http://www.ncbi.nlm.nih.gov/pubmed/3102698?tool=bestpractice.com
[74]Vogh BP, Langham MR Jr. The effect of furosemide and bumetanide on cerebrospinal fluid formation. Brain Res. 1981 Sep 21;221(1):171-83.
http://www.ncbi.nlm.nih.gov/pubmed/6791768?tool=bestpractice.com
The dose of furosemide can be increased gradually until the desired effect is obtained. Close monitoring of the serum level of potassium is recommended.
Furosemide appears to work both by producing diuresis and reducing sodium transport into the brain.[75]Buhrley LE, Reed DJ. The effect of furosemide on sodium-22 uptake into cerebrospinal fluid and brain. Exp Brain Res. 1972 Apr 27;14(5):503-10.
http://www.ncbi.nlm.nih.gov/pubmed/5047282?tool=bestpractice.com
Acetazolamide can be given with furosemide in cases of refractory disease, but close monitoring of serum potassium is necessary.[76]Schoeman JF. Childhood pseudotumor cerebri: clinical and intracranial pressure response to acetazolamide and furosemide treatment in a case series. J Child Neurol. 1994 Apr;9(2):130-4.
http://www.ncbi.nlm.nih.gov/pubmed/8006361?tool=bestpractice.com
[77]Schoeman J, Donald P, van Zyl L, et al. Tuberculous hydrocephalus: comparison of different treatments with regard to ICP, ventricular size and clinical outcome. Dev Med Child Neurol. 1991 May;33(5):396-405.
http://www.ncbi.nlm.nih.gov/pubmed/2065826?tool=bestpractice.com
Topiramate
This drug has weak carbonic anhydrase activity, and a fortunate adverse effect is weight loss. Topiramate may have efficacy similar to acetazolamide.[55]Hoffmann J, Mollan SP, Paemeleire K, et al. European Headache Federation guideline on idiopathic intracranial hypertension. J Headache Pain. 2018 Oct 8;19(1):93.
https://thejournalofheadacheandpain.biomedcentral.com/articles/10.1186/s10194-018-0919-2
http://www.ncbi.nlm.nih.gov/pubmed/30298346?tool=bestpractice.com
[78]Celebisoy N, Gokcay F, Sirin H, et al. Treatment of idiopathic intracranial hypertension: topiramate vs acetazolamide, an open-label study. Acta Neurol Scand. 2007 Nov;116(5):322-7.
http://www.ncbi.nlm.nih.gov/pubmed/17922725?tool=bestpractice.com
It can be useful for its migraine prophylaxis as well as carbonic anhydrase inhibition. However, topiramate can cause confusion, drowsiness, and, rarely, acute angle closure glaucoma.
Headache
Headaches may transiently improve after a single lumbar puncture, but often remain as a major management problem even after medications have been given to reduce papilledema and CSF pressure.
Pharmacotherapy
Beta-blockers or calcium-channel blockers should be avoided, as they may decrease perfusion of the optic nerve head. Tricyclic antidepressants can be used, but because weight gain is an adverse effect they should be prescribed at a low dosage. They can also cause urinary retention, dry mouth, and sedation, although these are seldom a significant problem. Nonsteroidal anti-inflammatory drugs, such as naproxen, can also be used, but should be taken only 2 days per week to prevent rebound headache.
Patients with a history of migraine, or analgesic- or caffeine-rebound headaches, may require intravenous dihydroergotamine in combination with metoclopramide. Metoclopramide should be used for up to 5 days only, in order to minimize the risk of neurologic and other adverse effects.[79]European Medicines Agency. European Medicines Agency recommends changes to the use of metoclopramide. July 2013 [internet publication].
http://www.ema.europa.eu/ema/index.jsp?curl=pages/news_and_events/news/2013/07/news_detail_001854.jsp
It is not uncommon for papilledema to resolve and analgesic-overuse headaches to remain.
Shunting procedures
Various shunting procedures have been used for intractable headache or failed medical therapy, including lumbar subarachnoid-peritoneal, cisternoatrial, ventriculoatrial, ventriculojugular, and ventriculoperitoneal shunts.[80]Eggenberger ER, Miller NR, Vitale S. Lumboperitoneal shunt for the treatment of pseudotumor cerebri. Neurology. 1996 Jun;46(6):1524-30.
http://www.ncbi.nlm.nih.gov/pubmed/8649541?tool=bestpractice.com
[81]Rosenberg M, Smith C, Beck R, et al. The efficacy of shunting procedures in pseudotumor cerebri (abstract). Neurology. 1989;39(suppl 1):S209.[82]Johnston I, Besser M, Morgan MK. Cerebrospinal fluid diversion in the treatment of benign intracranial hypertension. J Neurosurg. 1988 Aug;69(2):195-202.
http://www.ncbi.nlm.nih.gov/pubmed/3392566?tool=bestpractice.com
[83]Burgett RA, Purvin VA, Kawasaki A. Lumboperitoneal shunting for pseudotumor cerebri. Neurology. 1997 Sep;49(3):734-9.
http://www.ncbi.nlm.nih.gov/pubmed/9305333?tool=bestpractice.com
[84]McGirt MJ, Woodworth G, Thomas G, et al. Cerebrospinal fluid shunt placement for pseudotumor cerebri-associated intractable headache: predictors of treatment response and an analysis of long-term outcomes. J Neurosurg. 2004 Oct;101(4):627-32.
http://www.ncbi.nlm.nih.gov/pubmed/15481717?tool=bestpractice.com
The most common complications are shunt occlusion and intracranial hypotension. Shunt malfunction can also be accompanied by severe loss of vision. Less common complications are back pain, abdominal pain, infection of the disk space, meningitis, disconnection of tubing, and descent of the cerebellar tonsils. Although CSF diversion may reduce visual decline and improve visual acuity, 68% patients continue to experience headaches 6 months post procedure.[85]Sinclair AJ, Kuruvath S, Sen D, et al. Is cerebrospinal fluid shunting in idiopathic intracranial hypertension worthwhile? A 10-year review. Cephalalgia. 2011 Dec;31(16):1627-33.
http://www.ncbi.nlm.nih.gov/pubmed/21968519?tool=bestpractice.com
Do not overlook the possibility of analgesic- or caffeine-rebound headache in these patients.
Progressive visual loss
If patients lose vision in spite of maximal medical therapy, surgical treatment by optic nerve sheath fenestration or CSF shunting can be done; both procedures have benefits and risks. The effectiveness of both techniques has been demonstrated in large case studies.[86]Goh KY, Schatz NJ, Glaser JS. Optic nerve sheath fenestration for pseudotumor cerebri. J Neuroophthalmol. 1997 Jun;17(2):86-91.
http://www.ncbi.nlm.nih.gov/pubmed/9176777?tool=bestpractice.com
[87]Acheson JF, Green WT, Sanders MD. Optic nerve sheath decompression for the treatment of visual failure in chronic raised intracranial pressure. J Neurol Neurosurg Psychiatry. 1994 Nov;57(11):1426-9.
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC1073203
http://www.ncbi.nlm.nih.gov/pubmed/7964827?tool=bestpractice.com
[88]Plotnik JL, Kosmorsky GS. Operative complications of optic nerve sheath decompression. Ophthalmology. 1993 May;100(5):683-90.
http://www.ncbi.nlm.nih.gov/pubmed/8493011?tool=bestpractice.com
[89]Rizzo JF 3rd, Lessell S. Choroidal infarction after optic nerve sheath fenestration. Ophthalmology. 1994 Sep;101(9):1622-6.
http://www.ncbi.nlm.nih.gov/pubmed/8090466?tool=bestpractice.com
[90]Spoor TC, McHenry JG. Long-term effectiveness of optic nerve sheath decompression for pseudotumor cerebri. Arch Ophthalmol. 1993 May;111(5):632-5.
http://www.ncbi.nlm.nih.gov/pubmed/8489443?tool=bestpractice.com
[91]Fonseca PL, Rigamonti D, Miller NR, et al. Visual outcomes of surgical intervention for pseudotumour cerebri: optic nerve sheath fenestration versus cerebrospinal fluid diversion. Br J Ophthalmol. 2014 Oct;98(10):1360-3.
http://www.ncbi.nlm.nih.gov/pubmed/24820047?tool=bestpractice.com
[92]Huang LC, Winter TW, Herro AM, et al. Ventriculoperitoneal shunt as a treatment of visual loss in idiopathic intracranial hypertension. J Neuroophthalmol. 2014 Sep;34(3):223-8.
http://www.ncbi.nlm.nih.gov/pubmed/24637911?tool=bestpractice.com
[93]Niotakis G, Grigoratos D, Chandler C, et al. CSF diversion in refractory idiopathic intracranial hypertension: single-centre experience and review of efficacy. Childs Nerv Syst. 2013 Feb;29(2):263-7.
http://www.ncbi.nlm.nih.gov/pubmed/22918619?tool=bestpractice.com
[94]Rizzo JL, Lam KV, Wall M, et al. Perimetry, retinal nerve fiber layer thickness and papilledema grade after cerebrospinal fluid shunting in patients with idiopathic intracranial hypertension. J Neuroophthalmol. 2015 Mar;35(1):22-5.
http://www.ncbi.nlm.nih.gov/pubmed/25295682?tool=bestpractice.com
The clinical course of optic nerve sheath fenestration awaits further study, as meta-analysis of retrospective case series also shows approximately 10% of patients lose vision despite this procedure;[95]Wall M, Johnson CA, Kutzko KE, et al. Long- and short-term variability of automated perimetry results in patients with optic neuritis and healthy subjects. Arch Ophthalmol. 1998 Jan;116(1):53-61.
http://www.ncbi.nlm.nih.gov/pubmed/9445208?tool=bestpractice.com
a similar percentage of vision loss occurs with CSF shunting.[1]Wall M. Idiopathic intracranial hypertension. Neurol Clin. 2010 Aug;28(3):593-617.
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2908600
http://www.ncbi.nlm.nih.gov/pubmed/20637991?tool=bestpractice.com
Late deterioration requiring refenestration appears to be uncommon.
Optic nerve sheath fenestration usually produces immediate results, with improvement in vision occurring over several months. The procedure is usually performed on the eye with the worse vision, and often vision recovers and papilledema is decreased in the unoperated eye as well. This improvement in the nonoperated eye can persist for months or even years, but is often less pronounced than in the operated eye. Complications include loss of vision in the perioperative period, ocular motility disorders, and tonic pupils. Loss of vision may be related to a fall in arterial blood pressure.
Patients should be evaluated by a neuro-ophthalmologist if available; otherwise, a neurologist should collaborate with an ophthalmologist. The ophthalmologist should assess visual function by perimetry and monitor the degree of papilledema with serial fundus photographs if available (if not, Frisén grading can be used). Visual evoked potential is insensitive for monitoring the loss of vision associated with IIH and should not be used.
Other neurologic symptoms and signs
Prisms can be given for the diplopia of sixth cranial nerve palsy, which usually resolves with treatment. Nonsteroidal anti-inflammatory drugs can be used for neck pain but should be limited to only 2 days per week if there is concomitant headache. Pulse synchronous tinnitus usually responds to weight loss and medical treatments; in persistent tinnitus due to the transverse venous sinus stenosis related to the increased intracranial pressure, transverse sinus stenting may be indicated.
Pregnancy
Pregnant women are generally given the same treatments as for nonpregnant patients; however, caution is advised.[96]Digre KB, Varner MW, Corbett JJ. Pseudotumor cerebri and pregnancy. Neurology. 1984 Jun;34(6):721-9.
http://www.ncbi.nlm.nih.gov/pubmed/6539432?tool=bestpractice.com
There are no adequate studies of acetazolamide in pregnant women. It has been shown to be teratogenic in animals, and there have been case reports of congenital malformations, neonatal electrolyte disturbances, and low birth weight in humans.[97]Lee AG, Pless M, Falardeau J, et al. The use of acetazolamide in idiopathic intracranial hypertension during pregnancy. Am J Ophthalmol. 2005 May;139(5):855-9.
http://www.ncbi.nlm.nih.gov/pubmed/15860291?tool=bestpractice.com
Acetazolamide may be used after the first trimester (e.g., in cases where the patient is losing vision or has high-grade papilledema), but only if the benefits outweigh the potential risks to the fetus. There are no well-controlled studies of furosemide in pregnant women.[98]Thurtell MJ, Wall M. Idiopathic intracranial hypertension (pseudotumor cerebri): recognition, treatment, and ongoing management. Curr Treat Options Neurol. 2013 Feb;15(1):1-12.
https://www.ncbi.nlm.nih.gov/labs/pmc/articles/PMC3554852
http://www.ncbi.nlm.nih.gov/pubmed/23136035?tool=bestpractice.com
Again, it should only be used if the benefits outweigh the potential risks to the fetus. Topiramate is not recommended in pregnant women due to an increased risk of cleft lip and/or cleft palate in the fetus, as well as other issues (e.g., small for gestational age, maternal metabolic acidosis, preterm labor).[46]Mollan SP, Davies B, Silver NC, et al. Idiopathic intracranial hypertension: consensus guidelines on management. J Neurol Neurosurg Psychiatry. 2018 Oct;89(10):1088-100.
https://jnnp.bmj.com/content/89/10/1088.long
http://www.ncbi.nlm.nih.gov/pubmed/29903905?tool=bestpractice.com
However, there may be circumstances where the use of topiramate is justified because the benefits of treatment outweigh the risks to the fetus. Always discuss the risk and benefits of drug treatments with pregnant women before initiating therapy.
Surgery in pregnant women can be done under local anesthesia, so need not be delayed. Pregnant women with IIH do not have an increased rate of spontaneous abortion.[99]Tang RA, Dorotheo EU, Schiffman JS, et al. Medical and surgical management of idiopathic intracranial hypertension in pregnancy. Curr Neurol Neurosci Rep. 2004 Sep;4(5):398-409.
http://www.ncbi.nlm.nih.gov/pubmed/15324607?tool=bestpractice.com
Despite the presence of elevated intracranial pressure, neuraxial (spinal and epidural) anesthesia can be used without adverse effects (including uncal herniation) for cesarean section and pain relief during labor, even in patients with CSF diversion devices in situ.[100]Karmaniolou I, Petropoulos G, Theodoraki K. Management of idiopathic intracranial hypertension in parturients: anesthetic considerations. Can J Anaesth. 2011 Jul;58(7):650.
http://www.ncbi.nlm.nih.gov/pubmed/21519980?tool=bestpractice.com